Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | EVP, CHIEF COMMERCIAL OFFICER | February 27, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 27, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 83,171 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Tax withholding · Disposed 23,812 · Balance 83,171 |
| Common Stock, $0.01 par valueSEC Table I · non-derivative | IndirectBy spouse in trust | 1,338 |
Reported balance
Holding disclosure · report date 2026-02-27 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,338 F1: The reporting person disclaims beneficial ownership of all securities held by his spouse. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person disclaims beneficial ownership of all securities held by his spouse.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 15, 2021 Filed Dec 17, 2021 22:01 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 2,152 | $128.00 | $275,456.00 |
DisclosureSEC source: 0001179110-21-011109 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,104 Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 1,713 | $124.15 | $212,668.95 |
DisclosureSEC source: 0001179110-21-010956 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,256 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:26 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 13,773 | $108.59 | $1,495,575.64 |
DisclosureSEC source: 0001179110-21-002594 · edgar.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,969 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.34 to $108.88 inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:26 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 10,957 | $107.74 | $1,180,507.18 |
DisclosureSEC source: 0001179110-21-002594 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,742 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 43,478 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · derivative · entry 6 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,478 Underlying: Common · 43,478 shares Expires 2031-02-17 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 14,493 on February 18, 2022 14,493 on February 18, 2023, and 14,492 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 7,486 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · nonDerivative · entry 4 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,699 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · nonDerivative · entry 3 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,213 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,037 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:19 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 10,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002048 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,067 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 18:15 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionOption (Right to buy) · Derivative | 25,290 | $0.00 Strike: $51.42 | $0.00 |
DisclosureSEC source: 0001179110-20-012333 · edgar.xml · derivative · entry 4 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 25,290 shares Expires 2024-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 18:15 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 25,290 | $105.00 | $2,655,450.00 |
DisclosureSEC source: 0001179110-20-012333 · edgar.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,969 Read SEC document |
| December 29, 2020 Filed Dec 31, 2020 18:15 UTC | AbbVie Inc. ABBV · Entity 2800 | Exercise / conversionCommon Stock, $0.01 par value | 25,290 | $51.42 | $1,300,411.80 |
DisclosureSEC source: 0001179110-20-012333 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,259 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 21:31 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 1,791 | $108.67 | $194,627.97 |
DisclosureSEC source: 0001179110-20-011832 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,969 Read SEC document |
| May 12, 2020 Filed May 12, 2020 21:44 UTC | AbbVie Inc. ABBV · Entity 2800 | SaleCommon Stock, $0.01 par value | 23,024 | $90.00 | $2,072,210.65 |
DisclosureSEC source: 0001179110-20-005830 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,760 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.00 to $90.01, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:57 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 9,703 | $85.42 | $828,830.26 |
DisclosureSEC source: 0001179110-20-002868 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,784 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 49,099 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-20-002128 · edgar.xml · derivative · entry 6 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,099 Underlying: Common Stock · 49,099 shares Expires 2030-02-19 F6 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,176 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002128 · edgar.xml · nonDerivative · entry 4 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,487 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002128 · edgar.xml · nonDerivative · entry 3 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,311 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 3,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002128 · edgar.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,341 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 22:59 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 10,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002128 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,431 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| December 10, 2019 Filed Dec 12, 2019 21:22 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 1,713 | $86.44 | $148,071.72 |
DisclosureSEC source: 0001179110-19-012716 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,591 Read SEC document |
| August 16, 2019 Filed Aug 20, 2019 20:16 UTC | AbbVie Inc. ABBV · Entity 2800 | PurchaseCommon stock, $0.01 par value | 15,552 | $64.44 | $1,002,169.32 |
DisclosureSEC source: 0001179110-19-009703 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,304 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:00 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon stock, $0.01 par value | 6,907 | $79.41 | $548,484.87 |
DisclosureSEC source: 0001179110-19-003097 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,752 Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to buy) · Derivative | 25,700 | $0.00 Strike: $79.02 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · derivative · entry 5 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,700 Underlying: Common Stock · 25,700 shares Expires 2029-02-20 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,567 on February 21, 2020, 8,566 on February 21, 2021, and 8,567 on February 21, 2022. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 2,970 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · nonDerivative · entry 4 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,659 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 3,909 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · nonDerivative · entry 3 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,689 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 3,645 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · nonDerivative · entry 2 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,780 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| February 21, 2019 Filed Feb 22, 2019 22:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 5,062 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002363 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,135 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2016. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2019. Read SEC document |
| December 10, 2018 Filed Dec 12, 2018 23:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 11,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013777 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,073 F1 · shares: These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in annual increments of 21,514 on 12/09/2016, 21,513 on 12/09/2017, and 21,513 on 12/09/2018, and include the right to have stock withheld for tax purposes. Read SEC document |
| December 10, 2018 Filed Dec 13, 2018 01:38 UTC Amendment | AbbVie Inc. ABBV · Entity 2800 | GrantCommon stock, $0.01 par value | 11,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-013808 · edgar.xml · nonDerivative · entry 1 Stewart Jeffrey Ryan · CIK 0001761675 · SVP, US Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,073 F1 · shares: These securities represent restricted stock units granted under the AbbVie 2013 Incentive Stock Program. They vest in annual increments of 3,865 shares on each of 12/10/2019, 12/10/2020 and 12/10/2021, and include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.